Research shows significant links between ST6GAL1 and HR, HER2 in breast carcinomas, suggesting implications for treatment resistance.
This research is one of the first studies to use ST6GAL1 in preoperative biopsies of patients not scheduled for neoadjuvant treatment. This study revealed highly significant associations of ST6GAL1 expression with HR, HER2, and molecular subtyping. Future studies are recommended to clarify the possible role of ST6GAL1 in resistance to HR and HER2-targeted and other chemotherapeutic agents in BCs.
No takes yet. Share an insight, caveat, or question.
Ömeroğlu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: